As of Oct 02
| +3.12 / +7.62%|
The 8 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 65.00, with a high estimate of 86.00 and a low estimate of 55.00. The median estimate represents a +47.49% increase from the last price of 44.07.
The current consensus among 9 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.